CohBar Nominates CB5138 Analog as Lead Clinical Candidate for Idiopathic Pulmonary Fibrosis and other Fibrotic Diseases
MENLO PARK, Calif., March 16, 2021 (GLOBE NEWSWIRE) CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the selection of CB5138-3 as its lead candidate for advancement into IND-enabling activities. CB5138-3 is a CB5138 Analog, a novel class of molecules derived from a natural, mitochondrially encoded peptide source discovered by CohBar, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. IPF is a chronic, progressive, debilitating and usually fatal interstitial lung disease that affects approximately 100,000 people in the U.S. This orphan disease results in fibrotic scarring of the lungs.
crimes and misdemeanors. it did fin it did begin with the mueller investigation and there is so much more to be investigated but the actions that we read about this morning took place literally right after the mueller testimony, the mueller report. what does that tell snu the president s never been held accountable for his wrongdoing and if he thinks that he apparently thought that the special counsel didn t ding him sufficient so he could go on to higher crimes and higher misdemeanors. in this lengthy 11-page document that the justice department released from the assistant attorney general office of legal counsel steven engle, he suggested that the whistle-blower complaint focused largely on that one phone conversation between the president of the united states and the president of ukraine, the rough summary of which we got earlier in the day. is that true? is it simply based on that or was there a lot more in the whistle-blower complaint? you know, i m going to follow the rul